See more : Semantix, Inc. (STIXF) Income Statement Analysis – Financial Results
Complete financial analysis of Zealand Pharma A/S (ZLDPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zealand Pharma A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pacific Gas and Electric Company (PCG-PD) Income Statement Analysis – Financial Results
- SUPERIOR PRIMA SUKSES TBK (BLES.JK) Income Statement Analysis – Financial Results
- Deccan Health Care Limited (DECCAN.BO) Income Statement Analysis – Financial Results
- Cyteir Therapeutics, Inc. (CYT) Income Statement Analysis – Financial Results
- Uni-President China Holdings Ltd (UNPSF) Income Statement Analysis – Financial Results
Zealand Pharma A/S (ZLDPF)
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 342.79M | 103.99M | 292.57M | 353.31M | 41.33M | 37.98M | 139.78M | 234.78M | 187.68M | 153.77M | 6.57M | 223.57M | 142.28M | 87.36M | 25.32M | 56.26M | 59.92M |
| Cost of Revenue | 19.17M | 30.71M | 118.81M | 90.57M | 415.00K | 180.24M | 14.63M | 31.46M | 22.27M | 13.78M | 872.00K | 15.93M | 112.00K | 11.20M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 323.61M | 73.28M | 173.75M | 262.75M | 40.92M | -142.26M | 125.15M | 203.32M | 165.41M | 140.00M | 5.70M | 207.63M | 142.17M | 76.15M | 25.32M | 56.26M | 59.92M |
| Gross Profit Ratio | 94.41% | 70.47% | 59.39% | 74.37% | 99.00% | -374.60% | 89.53% | 86.60% | 88.14% | 91.04% | 86.74% | 92.87% | 99.92% | 87.18% | 100.00% | 100.00% | 100.00% |
| Research & Development | 684.90M | 614.04M | 588.45M | 604.08M | 561.42M | 438.22M | 324.67M | 268.16M | 214.96M | 180.04M | 164.47M | 182.76M | 126.94M | 151.28M | 93.09M | 85.76M | 105.14M |
| General & Administrative | 73.80M | 274.24M | 260.99M | 202.77M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Selling & Marketing | 16.05M | 32.30M | 375.27M | 285.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.85M | 306.54M | 636.26M | 488.03M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Other Expenses | 121.10M | 0.00 | -759.00K | -602.00K | -444.00K | 1.10B | 0.00 | 777.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 895.85M | 920.59M | 1.22B | 1.09B | 628.86M | 515.59M | 371.53M | 318.97M | 246.74M | 213.53M | 191.32M | 175.24M | 133.41M | 196.05M | 105.24M | 100.95M | 122.45M |
| Cost & Expenses | 915.03M | 920.59M | 1.34B | 1.18B | 629.28M | 695.82M | 386.16M | 350.42M | 269.00M | 227.31M | 192.19M | 191.17M | 133.52M | 196.05M | 105.24M | 100.95M | 122.45M |
| Interest Income | 45.32M | 6.54M | 44.00K | 895.00K | 5.41M | 4.26M | 2.05M | 592.00K | 139.00K | 719.00K | 3.04M | 5.63M | 6.56M | 4.13M | 4.32M | 11.21M | 0.00 |
| Interest Expense | 24.89M | 56.46M | 4.09M | 2.90M | 3.21M | 15.08M | 18.91M | 32.16M | 32.71M | 2.02M | 81.00K | 186.00K | 1.95M | 63.00K | 104.00K | 257.00K | 0.00 |
| Depreciation & Amortization | 25.09M | 30.71M | 25.12M | 42.69M | 13.54M | 4.51M | 4.76M | 5.41M | 6.22M | 5.93M | 5.91M | 5.32M | 4.13M | 4.13M | 3.69M | 3.28M | 0.00 |
| EBITDA | -658.89M | -665.26M | -711.85M | -627.94M | -562.64M | -442.00M | -246.28M | -118.27M | -81.25M | -64.54M | -177.68M | 41.92M | 14.68M | -104.57M | -76.25M | -44.69M | -62.53M |
| EBITDA Ratio | -192.22% | -639.76% | -332.94% | -246.80% | -1,361.23% | -1,761.72% | -176.19% | -50.37% | -45.11% | -43.50% | -2,687.30% | 19.39% | 13.67% | -119.71% | -284.06% | -79.43% | -104.35% |
| Operating Income | -572.24M | -816.60M | -1.05B | -828.76M | -587.94M | 652.39M | -246.38M | -115.65M | -81.33M | -73.54M | -185.62M | 32.40M | 8.76M | -108.70M | -79.93M | -44.69M | -62.53M |
| Operating Income Ratio | -166.94% | -785.30% | -358.96% | -234.57% | -1,422.45% | 1,717.86% | -176.27% | -49.26% | -43.33% | -47.82% | -2,823.52% | 14.49% | 6.16% | -124.43% | -315.67% | -79.43% | -104.35% |
| Total Other Income/Expenses | -136.63M | -134.89M | 25.43M | -47.29M | 11.27M | -27.33M | -31.39M | -43.76M | -38.51M | 1.05M | 1.94M | 3.98M | 4.61M | 4.06M | 4.86M | 10.96M | 7.53M |
| Income Before Tax | -708.87M | -972.04M | -1.03B | -839.65M | -576.68M | 625.06M | -277.77M | -159.41M | -119.83M | -72.49M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Income Before Tax Ratio | -206.79% | -934.78% | -351.01% | -237.65% | -1,395.20% | 1,645.88% | -198.73% | -67.90% | -63.85% | -47.14% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| Income Tax Expense | -5.13M | -6.43M | -8.79M | 7.08M | -5.14M | 43.77M | -5.50M | -5.50M | -5.88M | -7.50M | 81.00K | 186.00K | 6.56M | 0.00 | 4.32M | -3.28M | 0.00 |
| Net Income | -703.74M | -965.61M | -1.02B | -846.73M | -571.54M | 581.28M | -272.27M | -153.91M | -113.96M | -64.99M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Net Income Ratio | -205.30% | -928.60% | -348.01% | -239.65% | -1,382.77% | 1,530.61% | -194.79% | -65.56% | -60.72% | -42.26% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| EPS | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.61 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| EPS Diluted | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.60 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| Weighted Avg Shares Out | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.69M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.63M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
| Weighted Avg Shares Out (Dil) | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.70M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.73M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
Zealand Pharma seeks big pharma partners for obesity drug candidate
Denmark's Zealand Pharma is set to start talks in the second half of this year with other pharmaceutical companies for potential partnerships to develop and commercialize its weight-loss drug petrelintide, its CEO told Reuters on Thursday.
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
Press release – 7 / 2024 Zealand Pharma Appoints Eric Cox as Chief Commercial Officer Copenhagen, Denmark, 29 July 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today...
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
Zealand Pharma AS (ZLDPF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Weight loss drug contender Zealand Pharma jumps 23% on trial results
Zealand Pharma shares popped on Friday on positive weight loss results from long-acting amylin analog petrelintide. The company said petrelintide may produce similar weight loss results and a "better patient experience" than GLP-1RA-based treatments, which include Novo Nordisk's Ozempic and...
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drugs.
Zealand Pharma's drug reduces weight by 8.6% in early-stage study
Zealand Pharma said on Thursday an early-stage study showed a high dose of its drug helped reduce weight by an average 8.6% after 16 weekly doses.
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Body weight reductions of up to a mean of 8.6% with high...
Zealand Pharma says drug shows improvement in fatty liver disease patients
Denmark's Zealand Pharma said on Thursday its experimental weight-loss drug showed an improvement in patients with a type of fatty liver disease after results from a mid-stage study were leaked, sending its shares up nearly 7%.
Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript
Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2024 Results Conference Call May 16, 2024 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO David Kendall - CMO Henriette Wennicke - CFO Conference Call Participants Rajan Sharma...
Source: https://incomestatements.info
Category: Stock Reports
What are the future financial projections for Zealand Pharma?
Zealand Pharma AS (OCSE:ZEAL) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $54.77 million, and the earnings are expected to come in at -$4.06 per share.
What is Zealand Pharma’s revenue for 2024?
Revenue estimates for Zealand Pharma AS (OCSE:ZEAL) have declined from $190.56 million to $163.57 million for the full year 2024 and from $0.83 billion to $0.73 billion for 2025 over the past 90 days.